🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseHas anyone dealt with alt normalization rates on glp-1?

Has anyone dealt with alt normalization rates on glp-1?

laura_annarbor Fri, Jan 9, 2026 at 9:24 PM 23 replies 1,414 viewsPage 1 of 5
laura_annarbor
Member
189
890
Dec 2024
Ann Arbor, MI
Jan 9, 2026 at 9:24 PM#1

Fatty liver on an incidental scan two years ago and nobody followed it up. Now that I am losing weight I would like to know what to re-measure.

The narrow version of the question is whether normalised enzymes tell you anything about fibrosis, and what the right follow-up measurement is.

Not looking for reassurance. Looking for the part I have got wrong.

37 7labquiet_amy, emily_PDX, Dr.SleepRoch and 34 others
Reply Quote Save Share Report
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
Jan 9, 2026 at 10:21 PM#2
laura_annarbor said:
Fatty liver on an incidental scan two years ago and nobody followed it up.

ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase 3 ATTAIN trial. NASH resolution was achieved in ~60% of patients[1].

This is relevant to liver and MASH because survodutide's glucagon agonism specifically targets hepatic lipid metabolism — making it potentially the best-in-class agent for NASH/MAFLD comorbid with obesity.

References:
[1] Sanyal AJ, et al. N Engl J Med. 2024.
36 6NauseaFreeNow, SteveThurs, B12Beth and 33 others
Reply Quote Save Share Report
robert_kc
Member
289
1,234
Oct 2024
Kansas City, MO
Jan 9, 2026 at 11:18 PM#3
Dr.NateNeph said:
ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase…

NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy. The Phase 2b data for semaglutide showed 59% NASH resolution (vs 17% placebo) with 43% achieving fibrosis improvement[1].

Mechanism: GLP-1R activation reduces hepatic lipogenesis, increases fatty acid oxidation, reduces hepatic inflammation, and may directly reduce hepatic stellate cell activation (fibrosis pathway).

With resmetirom (thyroid hormone receptor agonist) recently approved for NASH, the field is evolving rapidly. Combination approaches (GLP-1 + resmetirom) are being explored.

References:
[1] Newsome PN, et al. N Engl J Med. 2021;384(12):1113-1124.
35 5DoseLogDan, SleepFixSam, PurityPaulOR and 32 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
DadBodDave
Member
187
923
Nov 2024
Ohio
Jan 10, 2026 at 12:15 AM#4
laura_annarbor said:
Fatty liver on an incidental scan two years ago and nobody followed it up.

Mine went the same way, slower.

Last edited: Jan 10, 2026 at 3:15 AM
34 4Dr.GastroMayo, JakeBK_lifts, DerekSJ_a1c and 31 others
Reply Quote Save Share Report
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Jan 10, 2026 at 5:43 AM#5

From the other side of the consultation, briefly.

Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Baseline: "Moderate hepatic steatosis, liver span 17.2cm, echogenic texture consistent with fat infiltration"
Month 8: "Mild steatosis, liver span 15.8cm, improved echogenicity"
Month 14: "Minimal to no steatosis, normal liver span 14.5cm, normal echotexture"

My liver literally shrank and de-fattened. The ultrasound tech said she's seen this pattern increasingly in GLP-1 patients and it's remarkable how consistently the fatty liver resolves.

33 3mel_PDX, Dr.AddMedPHL, newstart_MO and 30 others
Reply Quote Save Share Report
1235

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register